Combination of Saxagliptin and Metformin Is Effective as Initial Therapy in New-Onset Type 2 Diabetes Mellitus With Severe Hyperglycemia
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
CONTEXT: The efficacy/safety of combination oral agents in those with stable newly diagnosed type 2 diabetes (T2DM) with severe hyperglycemia is unknown. OBJECTIVE: The objective of the study was to assess glycemic and β-cell outcomes of two oral regimens. DESIGN: This was an open-label, randomized controlled trial with patients enrolled from 2011 through 2014 and followed up for 12 weeks. SETTING: The study was conducted at a major public hospital in Chicago. PATIENTS: One hundred adults with newly diagnosed T2DM and severe hyperglycemia (300-450 mg/dL) participated in the study. INTERVENTION: One hundred patients were randomized to receive Kombiglyze XR (saxagliptin 5 mg/metformin 2000 mg) daily (K group) vs glipizide XL 10 mg daily (G group). MAIN OUTCOME MEASURES: The measure was to maintain fasting/premeal glucose of less than 300 mg/dL up to 6 weeks and less than 250 mg/dL after 6 weeks until study end, and to have no return acute care-site visits. Those not meeting criteria were discontinued. Other outcomes included continuous glucose monitoring (CGM) and β-cell function estimates at start and study end. RESULTS: Baseline characteristics and primary outcome (K group 94%, G group 98%) were similar in both groups. The enrollment glucose (K group 343 mg/dL, G group 341 mg/dL) and glycated hemoglobin (K group 10.8%, G group 11%) declined by week 12 (K group 137 mg/dL, G group 129 mg/dL, and K group 6.8%, G group 6.9%), respectively. Homeostasis model assessment to assess basal insulin secretion and early insulin response improved severalfold (K group ×5.8, G group ×5.9, and K group ×9.5, G group ×13.1). In follow-up, the incidence of hypoglycemia was lower in the K group (self-monitored blood glucose: K group 8.0%, G group 24%; CGM: K group 20%, G group 46.5%) as were the number of episodes of hypoglycemia (self-monitored blood glucose: K group 4 in 12 weeks, G group 27 in 12 weeks; CGM: K group 0.28 per 24 h, G group 0.31 per 24 h). CONCLUSIONS: Kombiglyze XR and glipizide XL are efficacious in improving glycemia and β-cell function in stable newly diagnosed T2DM with severe hyperglycemia. The K group had less hypoglycemia. These results suggest that certain oral medications could be appropriate alternatives in treating severe hyperglycemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The main adverse effects noted with DPP-4 inhibitors are a small increase in upper respiratory tract viral infections (rates of nasopharyngitis were 6.4% with a DPP-4 inhibitor vs 6.1% with comparators; risk ratio, 1.2; 95% CI, 1.0–1.4) and a rare hypersensitivity reaction.1032”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1032]
In the citing paper
“Severe and disabling arthralgia has been reported in individuals taking DPP-4 inhibitors.1032”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1032]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Faires, J. D. (1978) · Cited by 6,711
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 3×
“Most published recommendations regarding patients with severe hyperglycemia suggest insulin therapy initiation (1, 2).”
BackgroundGender differences in the utilization of health care services.
Bertakis, K. D., Azari, R. S., Helms, L., Callahan, E. J., & Robbins, J. A. (2000) · PubMed · Cited by 1,464
The impact of medication regimen factors on adherence to chronic treatment: a review of literature
Ingersoll, K. S., & Cohen, J. (2008) · Journal of Behavioral Medicine · doi:10.1007/s10865-007-9147-y · Cited by 583
BRUNZELL, J. D., ROBERTSON, R. P., LERNER, R. L., HAZZARD, W. R., ENSINCK, J. W., BIERMAN, E. L., & PORTE, D. (1976) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-42-2-222 · Cited by 505
Kennedy, L. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79145-5 · Cited by 427
Correlates of Insulin Injection Omission
Peyrot, M., Rubin, R. R., Kruger, D. F., & Travis, L. B. (2010) · Diabetes Care · doi:10.2337/dc09-1348 · Cited by 407 · cited 1×
“Certain variables like administration of multiple injections, interference of daily activities by injection regimens, injection pain, and embarrassment are associated with poor medication adherence (26).”
BackgroundJensen, C. C., Cnop, M., Hull, R. L., Fujimoto, W. Y., Kahn, S. E., & the American Diabetes Association GENNID Study Group (2002) · Diabetes · doi:10.2337/diabetes.51.7.2170 · Cited by 312
Jadzinsky, M., Pfützner, A., Paz‐Pacheco, E., Xu, Z., Allen, E., Chen, R., & CV181‐039 Investigators (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01056.x · Cited by 296
Olson, L. K., Redmon, J. B., Towle, H. C., & Robertson, R. P. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116596 · Cited by 212
Chen, H.-S., Wu, T.-E., Jap, T.-S., Hsiao, L.-C., Lee, S.-H., & Lin, H.-D. (2008) · Diabetes Care · doi:10.2337/dc08-0075 · Cited by 165
Williams‐Herman, D., Johnson, J., Teng, R., Golm, G., Kaufman, K. D., Goldstein, B. J., & Amatruda, J. M. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01204.x · Cited by 153
Harmon, J. S., Gleason, C. E., Tanaka, Y., Poitout, V., & Robertson, R. P. (2001) · Diabetes · doi:10.2337/diabetes.50.11.2481 · Cited by 140
Williams-Herman, D., Johnson, J., Teng, R., Luo, E., Davies, M. J., Kaufman, K. D., Goldstein, B. J., & Amatruda, J. M. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802705679 · Cited by 127
Oxidative Stress Is a Mediator of Glucose Toxicity in Insulin-secreting Pancreatic Islet Cell Lines
Wu, L., Nicholson, W., Knobel, S. M., Steffner, R. J., May, J. M., Piston, D. W., & Powers, A. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m307097200 · Cited by 106
Determinants of glucose toxicity and its reversibility in the pancreatic islet β-cell line, HIT-T15
Gleason, C. E., Gonzalez, M., Harmon, J. S., & Robertson, R. P. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.279.5.e997 · Cited by 98
Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus
Hirshberg, B., Parker, A., Edelberg, H., Donovan, M., & Iqbal, N. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2502 · Cited by 55
Davies, M., & Speight, J. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01595.x · Cited by 54
Peters, A. L., & Davidson, M. B. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.7.8675555 · Cited by 37 · cited 2×
“Sulfonylureas were successful in lowering BG levels in patients with severe hyperglycemia in one combined retrospective/prospective study (4, 5).”
BackgroundBabu, A., Mehta, A., Guerrero, P., Chen, Z., Meyer, P. M., Koh, C. K., Roberts, R., Schaider, J., & Fogelfeld, L. (2009) · Endocrine Practice · doi:10.4158/ep09117.orr · Cited by 34 · cited 7×
“In the only prospective randomized trial, glipizide proved to be as effective as insulin in lowering quickly high BG levels (range of 300–700 mg/dL) in patients with a glycated hemoglobin (HbA1c) less than 13% (6).”
BackgroundInfluentialSelf-citationRosenstock, J., Gross, J. L., Aguilar-Salinas, C. A., Hissa, M. N., Berglind, N., Ravichandran, S., & Fleming, D. (2013) · Diabetic Medicine · doi:10.1111/dme.12267 · Cited by 31
Derosa, G., & Maffioli, P. (2011) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s16361 · Cited by 27
Karyekar, C. S., Frederich, R. C., & Ravichandran, S. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12212 · Cited by 18
Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia
Mintz, M. L., & Minervini, G. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.880674 · Cited by 6
Davidson, M. B. (1992) · PubMed Central · Cited by 4
Initial Management of Severe Hyperglycemia in Patients with Type 2 Diabetes: an Observational Study
King, W. M. I., Mcdermott, M., & Trujillo, J. M. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0036-9 · Cited by 3
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Drug–drug co-amorphous systems: An emerging formulation strategy for poorly water-soluble drugs
Wang, H., Zhao, P., Ma, R., Jia, J., & Fu, Q. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103883 · Cited by 53
The Role of Beta Cell Recovery in Type 2 Diabetes Remission
Suleiman, M., Marselli, L., Cnop, M., Eizirik, D. L., Luca, C. D., Femia, F. R., Tesi, M., Guerra, S. D., & Marchetti, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137435 · Cited by 49
Cai, X., Gao, X., Yang, W., Han, X., & Ji, L. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0493-2 · Cited by 47
Functional loss of pancreatic islets in type 2 diabetes: How can we halt it?
Marrano, N., Biondi, G., Cignarelli, A., Perrini, S., Laviola, L., Giorgino, F., & Natalicchio, A. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154304 · Cited by 41
Metadata
- Authors
- Amblee, A., Lious, D., & Fogelfeld, L.
- Affiliations
- Rush University Medical Center (US)
- Corresponding author
- Amblee, Ambika
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-06
- Volume
- 101
- Issue
- 6
- Pages
- 2528-2535
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2346939334
- Cited by
- 16
- References
- 29
- Citations by year
- 2026: 2 · 2024: 3 · 2022: 3 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 1 · 2016: 2
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- saxagliptin, metformin, type 2 diabetes, new-onset diabetes, severe hyperglycemia, glipizide, initial treatment, glycemic control, beta-cell function, hypoglycemia, HbA1c, continuous glucose monitoring, HOMA-IR, DPP-4 inhibitors, sulfonylureas
- MeSH terms
- Adamantane, Adult, Blood Glucose, Diabetes Mellitus, Type 2, Dipeptides, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemic Agents, Insulin Resistance, Male, Metformin, Middle Aged, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.